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 Multiple scleroses (MS) is an inflammatory chronic disease where 
the body’s immune system attacks the myelin and destroys the central 
nervous system, causing the loss of the neural synchronization and functional 
disconnection among various brain regions. The cumulative evidence 
supports that physical therapy, has been shown to be beneficial in improving 
disability in patients with MS. The objective of this research was the review 
of the charts of the hospitalized MS patients, in order to find the positive 
effects of physiotherapy and its association with the progress of patient`s 
condition. This is a retrospective study conducted during January-December 
2015 in Vlore hospital, Albania. Two tailed P value, was used to find the 
significance of positive effects of physiotherapy and the progress of patients 
with MS. A value of P ≤ 0,05 was considered significant. There were nine 
charts, which met the study criteria and were included in the final analyses. 
The mean age of the MS patients was 39.77, SD±8.21, 6 males and 3 
females. The most prevalent clinical signs were loss of balance/dizziness, 
pain /body weakness/muscle rigidity, and memory loss/lack of concentration 
respectively 66.67%, 55.56% and 55.56%. Six patients had physiotherapy 
and statistically significance was found between patient`s condition and 
physiotherapy, p<0.05. The results of this study show that physical therapy 
was a very important factor for the progress of the patients in improving 
impairment and disabilities. 
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 Multiple scleroses (MS) is an inflammatory chronic disease where 
the body’s immune system attacks the myelin and destroys the central 
nervous system (brain and spinal cord). The damage of myelin slows or 
totally interrupts the transmission of the nervous signals through the cortical-
cortical and cortical-subcortical ways causing the loss of the neural 
synchronization and functional disconnection among various brain regions 
(NIH, 2001). MS is the most frequent cause of the no traumatic limited 
ability in young adults (Atlas of SM 2013) with a considerable social impact 
and economical consequences (M. Pugliatti et al., 2006). In the last five 
years the number of patients with MS increased with 10%, from 2.1 million 
in 2008 to 2.3 million in 2013. It is supposed that, in Europe there are 
630.000 people with MS. MS may develop at any age, but most of the people 
are diagnosed between ages of 20-40 (NIH,2001). The mean age, more 
frequently reported is around 30 years old. A small percentage of the MS 
patients, up to 5% are diagnosed during the teenage years or even younger 
(Chitnis Tl et al., 2013). A systematic review of the epidemiologic studies on 
MS shows that the ratio male/female of the incidence has risen from 1.4 in 
1955 to 2.3 in 2006 (Alonso A et al., 2008). The raise of the MS incidence in 
females, may be related with the impact of the environment factors 
associated to the urbanization (Kotzamani D et al 2012). According to the 
2013 report, on the global epidemiology of MS, the highest prevalence of 
MS is found in North America (140/100,000 residents) and Europe 
(108/100,000 residents) and the lowest in Sub Saharan Africa (2.1/100,000) 
and Eastern Asia (2.2/100,000) (. Atlas of SM 2013). The highest prevalence 
in Europe, is found in Sweden with 189 cases for 100,000 residents and the 
lowest in Albania with 22 cases for 100,000 residents (Alonso A et al.,2008). 
The first epidemiological study on the MS prevalence in Albania is 
performed in 1988 (M. Pugliatti et al 2006). According to this study, the 
prevalence of MS for 20 years (1968-1987) was 10 for 100,000 residents, 
while the mean yearly incidence was 0.5 for 100.000 residents (Rose AS et 
al 1976). In the last study conducted in Albania in 2008, it is noted an 
increase of MS cases in Saranda (Southwest of Albania) (Kruja J et 
al.,1994). The incidence is higher in females than males, finding are similar 
to other European states (Kruja J et al.,2010). In other hand a systemic 
review suggests that physiotherapy may be effective for the rehabilitation of 
people with progressive multiple sclerosis (Campbell E et al., 2016). 
 
Objective 
 To review the charts of the hospitalized MS patients in order to find 
the positive effects of physiotherapy and the progress of these patients.  
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Materials and Methods 
 This is a retrospective study based on the review of the hospital 
charts of the MS patients of Vlore hospital, Albania. The study was 
conducted during January-December 2015. We carefully reviewed each chart 
separately by taking into consideration all the variables. There were all 
together 9 charts, the main criteria was to include the diagnosed MS patients. 
 
Data analysis 
 Descriptive statistics, including frequencies, means, 95% coefficient 
interval (CI), and cross-tabulation tables were used for comparison of 
dependent and independent variables. Two tailed P value was used to find 
the significance of positive effects of physiotherapy and the progress of 
patients with MS. A value of P ≤ 0,05 was considered significant. Epi InfoTM 
7 software version 7.1.3.10, was used for statistical calculation. 
 
Ethical considerations 
 In order to conduct this study we had to get permission from the 
directors of the Regional Hospital of Vlore and the archive supervisor.  
 
Results  
 The total of charts included in analyes were nine.The mean age ( 
years) of patients with MS was 39.77, SD±8.21. 











Gender Female 3 33.33 [7.49–70.07] 
Male 6 66.67 [29.93–92.51] 
Civil status Single 6 66.67  [29.93–92.51] 
Married 3 33.33 [7.49–70.07] 
Place of living Village 4 44.44  [13.70–78.80] 
City 5 55.56 [21.20–86.30] 
Education level Elementary 4  44.44 [13.17–78.80] 
High school 2 22.22 [2.81–60.01] 
University 3 33.33 [7.49–70.07] 
Employment 
status 
Employed 2 22.22 [2.81–60.01] 
Unemployed 7 77.78 [39.99–97.19] 




Table 3. Hospital examinations of MS patients 
Variables Frequency (n) 
Percent 
(%) 95% CI  
No treatment 3 33.33% [7.49-70.07] 
Imagery examinations 2 22.22% [2.81-60.01] 
Lab examinations (blood, urine, 
uremi,creatinemy,glycemia) 3 33.33% [7.49-70.07] 
MRI 1 11.11% [0.28-48.25] 















Table 2. Clinical characteristics of the MS patients* 
Variables Frequency (n) Percent (%) 
Diagnoses MS 8 88.89 
Spastic tetra pareses 1 11.11 
Diagnoses of 
hospitalization  
Numbness and feet paralyses  3 33.33 
Urinary Incontinence 2 22.22 
Strong chest pain 2 22.22 
Urinary retention 2 22.22 
Clinical and periodical evaluation of 
the inability   
1 11.11 
Clinics Grave numbness of the extremities   1 11.11 
Loss of balance/dizziness 6 66.67 
Pain and body weakness/muscle 
rigidity   
5 55.56 
Memory loss/lack of concentration   5 55.56 
Depressive state 3 33.33 
Swallowing disorders 2 22.22 
Head aches 2 22.22 
Pain of the spinal cord 2 22.22 
Gastrointestinal disorders/vomiting 1 11.11 
Loss of sight 1 11.11 
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Table 4. The treatment of the patients 
Treatment before hospitalization Frequency (n) 
Percent 
(%) 
95% CI  
  
3 years without cortisone treatment   1 11.11 [0.28-48.25]  
Betaferon 2 22.22 [2.81-60.1]  
Betainterferone 1 11.11 [0.28-48.25]  
Dexametazone 1 11.11 [0.28-48.25]  
Interferon 3 33.33 [7.49-70.07]  






95% CI  
  
Betametazon 1 11.11 [0.28-48.25]  
Manitol/Betametazon 1 11.11 [2.28-48.25]  
No treatment  5 55.56 [21.20-86.30]  
Ranitidine/NaCl perfusions  1 11.11 [0.28-48.25]  
Salumedrol 1 11.11 [0.28-48.25]  





95% CI  
  
2 days 4 44.44 [13.70-78.80]  
3 days 1 11.11 [0.28-48.25]  
5 days 4 44.44 [13.70-78.80]  
*P values > 0.05 for all variables. 
 
Table 5. The effects of physiotherapy 
Physiotherapy Frequency (n) 
Percent 
(%) 
95% CI  
  
Yes  6 66.67 [29.93-92.51]  
No  3 33.33 [7.49-70.07]  






95% CI  
  
Only 5 sessions  1 16.67 [0.42-64.12]  
Some sessions  1 16.67 [0.42-64.12]  
Some sessions abroad  1 16.67 [0.42-64.12]  
Non specified  2 33.33 [4.33-77.72]  






Table 6. The association between  physiotherapy and  MS  patients condition  
Variables Yes( n) (%) No (n )(%) 2-tailed P 
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Table 7. The beginning and progress of the disease 






95% CI  
  
Acute and immediate 4 44.44 [13.70-78.80]  
Gradual 5 55.56 [21.20-86.30]  





95% CI  
  
Gradual 4 44.44 [13.70-78.80]  
Fast  1 55.56 [0.28-48.25]  
Fast the last 2 years  2 77.78 [2.81-60.01]  
Progressive  deterioration  1 88.89 [0.28-48.25]  
Very fast  1 44.44 [0.28-48.25]  






95% CI  
  
Yes 3 33.33 [7.49-70.07]  
No 6 66.67 [29.93-92.51]  





95% CI  
  
Yes 3 33.33 [7.49-70.07]  
No 6 66.67 [29.93-92.51]  
*P values > 0.05 for all variables. 
 
Discussion 
 The mean age of the MS patients in our study was 39.7 years, very 
close to mean age reported in literature, 20-40 years old (NIH, 2001). 
 Referring to the Table 1, the socio demographic characteristics of the 
MS patients included in the study shows that the number of males with MS 
is higher than the number of females, with a ration 2:1, which is contrary to 
the findings of the literature where the females dominate with a ratio 
4:1(AAN,2007). The literature shows that the number of MS patients is 
higher among people that belong to a lower education level and socio 
economic status, our study is similar too (Bjørnevik K et al.,2015). 44.44% 
of the patients in our study live in the village and 55.56% in the city, but the 
literature shows that there is a higher number of patients living in the village. 
Our study shows that the unemployed people are in 77.88% and the 
employed people are only 22.22%. We can see this evidence also in literature 
(Shahrbanian S et al.,2013). In our study we see that 66.67% of the patients 
are single, and only 33.33% are married. Being married at any point during 
the course of MS appears to confer a benefit in MS disease progression (Jill 
R Settle et al.,2014). 
 Referring to the Table 2, as in the literature (Bridget M Wilson, et 
al.,2015) the clinical signs of the hospitalized patients are similar to the ones 
that our patients have presented. In our study we see that depressive state is 
in 33.33% of the patients, and memory loss/lack of concentration in 55.56%, 
higher that reported in other similar studies, 24% (Amtmann D1 et al.,2014).  
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 Pain affects between 44% and 80% of people with MS and has a 
significant impact on their lives (Hirsh et al., 2009; O'Connor et al., 2008; 
Ehde et al., 2006) in our study we see that pain of the spinal cord is in 
22.22% of the patients, pain and body weakness/muscle rigidity is in 55.56 
% of the patients, headaches is in 22.22% of the patients. 
 The findings confirm (Guan XL et al.,2015), that more than one-third 
of the multiple sclerosis patients are suffering from swallowing difficulties. 
In our study, we can see that 22.22% of patients have swallowing disorders. 
In our study we don’t have any patient with pulmonary problems, even if 
gastrointestinal, musculoskeletal, and pulmonary comorbidities were 
common in the MS population (Ruth Ann Marrie et al.,2015) 
 Referring to tha Table 3, and from what we are referred by 
doctors neurologists and nurses, these patients due to the lack of specific 
treatments in our hospitals, they are kept there simply in observation (33.33 
% ) or when are subjected to laboratory analysis 33.33 %. All this done, in 
order to have the possibility of completing the documentation used to 
document the stated disability. Referring to the Table 4, we can see that 
the most prevalent treatments before hospitalization of the patients were 
with Betaferon and Interferon, respectively 22.22% and 33.33%. In literature 
we see that the treatment of MS is not so limited (Alan M Palmer et al., 
2013) The main characteristic feature noted at these patients is that all of 
them receive only symptomatic treatment while in hospital. Most of the 
treatments aim to reduce the symptoms that brought them to the hospital in 
the first place. 
 Referring to the Table 5 and 6, 66.67 % of the hospitalized patients 
have had some physiotherapy. These sessions, even though not regular, have 
improved their condition, p < 0.05. 
 Referring to the Table 7, the beginning and progress of the disease, 
in 44.44% of the patients is acute and immediate and in 55.56% is gradual. 
The results are similar with other studies, which confirm that the disease is 
different for everyone who has it (MSF, 2014). 
 The presence of meningeal signs are in 33.33% of the patients and we 
have done the evaluation of this signs, because as we have seen that in the 
literature exist a risk of under-diagnosis of Mood Disorders (MD), 
particularly Bipolar Disorders in MS (Carta MG et al., 2013).  
 In our study, we see that 66.67% of the patients have not a family 
history with MS, and 33.33% have a family history, Table 7. In literature 
studies show the higher aggregation of susceptibility variants in multi-case 
families compared to sporadic MS, using the most updated genetic 
information available for MS and a large and well-characterized familial 
dataset (Pierre-Antoine Gourraud et al.,2011). 
 




 Physical rehabilitation in multiple sclerosis (MS) patients is related 
to their quality of life. Based on evidence and the results of our study 
physical rehabilitation plays a beneficial role in improving disability in 
patients with MS. Physiotherapists and Nurses with the involvement of 
family members can contribute to create a multidisciplinary approach to set a 
Rehabilitation programme in accordance with the needs and the disabilities 
of MS patients.  
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